September 30, 2019 9:43pm

Yet, some of the oversold were recognized

Q3 ends in a tumultuous session after a rocky week with an Advance/Decline (A/D) line of 21/19 after Friday’s 14/27

The problem will be quarterly results being estimated, forecasted and missed

I make a commitment to provide need-to-know “facts in evidence” as equity’s volatility is one tactical signal for stocks.

 

There are a variety of end uses to sector forecasts; the most prominent, they are used to protect your portfolio’s life and value.

 

The Dow closed up +96.58 (+0.36%), the S&P closed up +19.45 (+0.50%) and the NASDAQ closed up +59.71 (+0.75%)

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday the IBB closed up +0.20% while the XBI closed down -0.21%
  • Friday the IBB closed down -0.78% while the XBI closed down -0.59%

 

Henry’omics:

It’s over … Q3 and September …

Sector equities and market indexes rose on Monday amid optimism around U.S.-China trade talks as Wall Street wrapped up a volatile Q3.

The fundamentals of “our” universe remain weak as investors’ skittishness has caused share pricing to fluctuate with the ebb and flow of … NO … news headlines!

 

The advance/decline line scenario of 45 covered companies:  

  • Monday the close was positive with an A/D line of 21/19, 3 flats and 2 acquired;
  • Friday the close was negative with an A/D line of 14/27, 2 flats and 2 acquired;

 

Decliners:

  • Sage Therapeutics (SAGE -$2.46);
  • CRISPER Therapeutics (SAGE -$1.37);
  • bluebird bio (BLUE -$0.99 after Friday’s -$3.02 after Thursday’s +$9.29);
  • BioMarin Pharmaceuticals (BMRN -$0.91 after Friday’s -$2.91);
  • Global Blood Therapeutics (GBT -$0.77 after Friday’s -$2.05 after Thursday’s -$2.93);

Incliners:

  • ReNeuron (RENE.L +$17.50 after Friday’s +$17.50 after Thursday’s +$15.00);
  • Regenxbio (RGNX +$2.25);
  • Ions Pharmaceuticals (IONS +$0.85);
  • BioLife Solutions (+$0.57);
  • AxoGen (AXGN +$0.39 after Friday’s -$1.66);

 

The percentage (%) indicators: 

  • Monday’s range of the 21 upside was +0.22% (FIXX) to +7.53% (RENE.L) while the 20 downside ranged from -0.43% (QURE) to -30.65% (HSGX);
  • Friday’s range of the 14 upside was +0.12% (RGNX) to +8.14% (RENE.L) while the 27 downside ranged from -0.30% (BOLD) to -30.65% (HSGX);

 

Upside volume stats:  to compare

  • Monday: 9 out of the 19 upside had higher than the 3 month average volume;
  • Friday: 4 out of the 14 upside had higher than the 3 month average volume;

Downside volume stats:

  • Monday: 4 out of the 19 downside had higher than the 3 month average volume;
  • Friday: 13 out of the 27 downside had higher than the 3 month average volume;

 

3 flat – ATHX, MDXG and NTLA with 2 acquired (AST & OSIR) and Spark Therapeutics’ (ONCE) acquisition by Roche is still being delayed (October?)

 

September’s sessions:

Monday closed POSITIVE with 19 decliners, 21 advancers, 3 flats and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 27 decliners, 14 advancers, 2 flats and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 32 decliners, 9 advancers, 2 flat and 2 acquired (AST & OSIR);

Wednesday closed NEGATIVE with 26 decliners, 16 advancers, 1 flat and 2 acquired (AST & OSIR);

Tuesday – not reported

Monday – not reported

Friday closed NEGATIVE with xx decliners, xx advancers, x flat and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 26 decliners, 14 advancers, 3 flats and 2 acquired (AST & OSIR);

Wednesday closed NEGATIVE with 31 decliners, 11 advancers, 1 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 27 decliners, 14 advancers, 2 flat and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 11 decliners, 32 advancers, 0 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 22 decliners, 18 advancers, 3 flats and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 26 decliners, 17 advancers, 0 flats and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 15 decliners, 26 advancers, 2 flats and 2 acquired (AST & OSIR);

Tuesday closed POSITIVE with 10 decliners, 31 advancers, 2 flats and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 18 decliners, 25 advancers, 0 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 26 decliners, 16 advancers, 1 flat and 2 acquired (AST & OSIR);

Thursday closed POSITIVE with 11 decliners, 31 advancers, 1 flat and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 20 decliners, 22 advancers, 1 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 29 decliners, 12 advancers, 2 flats and 2 acquired (AST & OSIR);

Monday was Labor Day

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.